絞り込み

17051

広告

Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.

著者 Woollacott IOC , Nicholas JM , Heslegrave A , Heller C , Foiani MS , Dick KM , Russell LL , Paterson RW , Keshavan A , Fox NC , Warren JD , Schott JM , Zetterberg H , Rohrer JD
Alzheimers Res Ther.2018 Aug 16 ; 10(1):79.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (2view , 1users)

Full Text Sources

Medical

Reliable biomarkers of frontotemporal dementia (FTD) are currently lacking. FTD may be associated with chronic immune dysfunction, microglial activation and raised inflammatory markers, particularly in progranulin (GRN) mutation carriers. Levels of soluble triggering receptor expressed on myeloid cells 2 (sTREM2) are elevated in Alzheimer's disease (AD), but they have not been fully explored in FTD.
PMID: 30111356 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード